Literature DB >> 31617453

Outcomes of Open Complex Ventral Hernia Repairs With Retromuscular Placement of Poly-4-Hydroxybutyrate Bioabsorbable Mesh.

Andrea Pakula1, Ruby Skinner1.   

Abstract

Purpose. Optimal technique and mesh selection still debated for complex ventral hernias. Limited data exists on bioabsorbable meshes in high-risk patients. We evaluated our experience. Methods. Retrospective review was conducted following institutional review board approval for ventral hernia repairs using a single bioabsorbable mesh between February 2014 and November 2017. Patient and hernia details characterized. Outcomes evaluated. Results. 20 ventral hernia repairs identified, 10 males, 10 females. Mean body mass index was 35 ± 7.4 kg/m2, and mean age 47 ± 13 years. Comorbid conditions were diabetes 35% and hypertension 40%. Fifty-five percent had American Society of Anesthesiologist scores of 3. Hernia Characteristics: Ventral Hernia Working Group Grade 3 hernias were 80%, and remainder grade 2. Forty percent of hernias were Centers for Disease Control class III, and remainder were class I and II. The mean defect size was 533 cm2 ± 500. Repair for prior open abdomens was 45%, recurrent hernias 20%, incisional 15%, incarcerated 10%, incisional with parastomal 5%, and primary ventral 5%. Concomitant bowel procedures in 8, (40%). All cases had retromuscular mesh placement (transversus abdominus release 65%, Rives-Stoppa 35%). Surgical site occurrences were 20% (surgical site infection 10%, seroma 10%). Overall hospital stay 5 ± 3 days. Ileus occurred in 20%. One postoperative death due to fatal arrhythmia. There were no recurrences with mean follow-up 21.1 months. Conclusions. Complex hernia repairs using bioabsorbable mesh were conducted in a small cohort of high-risk patients. These data demonstrate good outcomes with limited morbidity and mortality. There were no recurrences.

Entities:  

Keywords:  bioabsorbable mesh; biosynthetic mesh; complex abdominal wall reconstruction; contaminated ventral hernia; retromuscular hernia repair

Year:  2019        PMID: 31617453     DOI: 10.1177/1553350619881066

Source DB:  PubMed          Journal:  Surg Innov        ISSN: 1553-3506            Impact factor:   2.058


  6 in total

1.  An evaluation of clinical and quality of life outcomes after ventral hernia repair with poly-4-hydroxybutyrate mesh.

Authors:  A N Christopher; M P Morris; V Patel; J A Mellia; C Fowler; C A Messa; R B Broach; J P Fischer
Journal:  Hernia       Date:  2021-04-27       Impact factor: 4.739

Review 2.  Ventral hernia repair in high-risk patients and contaminated fields using a single mesh: proportional meta-analysis.

Authors:  S Morales-Conde; P Hernández-Granados; L Tallón-Aguilar; M Verdaguer-Tremolosa; M López-Cano
Journal:  Hernia       Date:  2022-09-13       Impact factor: 2.920

Review 3.  Prevention of incisional hernia at the site of stoma closure with different reinforcing mesh types: a systematic review and meta-analysis.

Authors:  Roberto Peltrini; Nicola Imperatore; Gaia Altieri; Simone Castiglioni; Maria Michela Di Nuzzo; Luciano Grimaldi; Michele D'Ambra; Ruggero Lionetti; Umberto Bracale; Francesco Corcione
Journal:  Hernia       Date:  2021-03-13       Impact factor: 4.739

Review 4.  Bioabsorbable mesh use in midline abdominal wall prophylaxis and repair achieving fascial closure: a cross-sectional review of stage of innovation.

Authors:  S K Kamarajah; N J Smart; I R Daniels; T D Pinkney; R L Harries
Journal:  Hernia       Date:  2020-05-24       Impact factor: 4.739

5.  Outcomes of Poly-4-hydroxybutyrate Mesh in Ventral Hernia Repair: A Systematic Review and Pooled Analysis.

Authors:  Joseph A Mellia; Sammy Othman; Hani I Naga; Charles A Messa; Omar Elfanagely; Yasmeen M Byrnes; Marten N Basta; John P Fischer
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-12-16

6.  Outcomes of biosynthetic absorbable mesh use in high risk CDC Class I ventral hernia repair: a single surgeon series.

Authors:  A Smith; K Slater
Journal:  Hernia       Date:  2021-06-08       Impact factor: 2.920

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.